English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Identifying Alzheimer's disease (AD) pharmacologic treatment options that effectively reduce the risk of mortality and hospitalization in real‐world settings is critical.    Methods  We compared donepezil, galantamine, memantine, oral rivastigmine, and transdermal rivastigmine with regard to all‐cause mortality and all‐cause hospitalization risk among fee‐for‐service Medicare beneficiaries with AD (aged ≥ 65 years) using a retrospective cohort study design. Our primary analysis was based on intention to treat (ITT), but we also present as‐treated analysis.    Results  In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as‐treated analysis. Difference in hazards of all‐cause hospitalization among index AD medication groups was observed in ITT analysis but not in as‐treated analysis.    Discussion  Significant differences exist in terms of mortality and hospitalization risk with different AD medication initiation in real‐world setting.

Alzheimer's disease medication and risk of all‐cause mortality and all‐cause hospitalization: A retrospective cohort study